The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Background Patients with cancer have an increased risk of complications from SARS-CoV-2
infection. Vaccination to prevent COVID-19 is recommended, but data on the …

COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and
mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence …

Background Patients with cancer are considered a priority group for Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination given their high risk of …

PURPOSE To provide real-world evidence on risks and outcomes of breakthrough COVID-
19 infections in vaccinated patients with cancer using the largest national cohort of COVID …

We and others have shown the significant impact of COVID-19 infection among patients with
a cancer diagnosis, with increased morbidity and mortality with advanced age, co …

Patients with hematological malignancies are at increased risk of severe COVID-19
outcomes due to compromised immune responses, but the insights of these studies have …